Rho GTPase activating protein 1 promotes apoptosis of myocardial cell in ischemic cardiomyopathy model.
Ischemic cardiomyopathy (ICM) cause heart failure by cardiac myocytes undergoing programmed cell death. It is generally believed that a therapy targeting apoptosis of cardiac myocytes would improve the prognosis of ischemic heart disease. This study aims to find out the roles of Rho GTPase Activating Protein 1 (ARHGAP1) in ICM. An ischemic myocardial cell, H9c2 cell model and an ICM rat model were established to explore the expression of ARHGAP1. Meanwhile, ARHGAP1 was over expressed in myocardial cells H9c2 to find out its functions. In our study, ARHGAP1 was found as a novel molecular that arose as a result of hypoxic conditions in the cell model as well as the rat model. ARHGAP1 overexpression induced apoptosis of cultured H9c2 under normal atmospheric conditions, which validate its role in ICM. Further study indicated that ARHGAP1 initiates the apoptosis pathway by regulating the cell death modulators B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax). Our results show that ARHGAP1 expression is closely related with apoptosis of myocardial cells, which in turn lead to ICM. ARHGAP1 will thus be a novel molecular marker of the hypoxia-induced apoptosis pathway and act as a potential therapeutic target for ICM.